Background: High-throughput assays that can infer neutralizing activity against
SARS-CoV-2 are of great importance for assessing the immunity induced by natural
infection and COVID-19 vaccines. We aimed to evaluate the performance and degree
of correlation of three fully automated anti-SARS-CoV-2 immunoassays with
neutralization activity using a surrogate virus-neutralizing test (sVNT) from
GenScript, targeting the receptor-binding domain. Methods: 110 sera collected
from PCR-confirmed asymptomatic COVID-19 individuals were tested for neutralizing
antibodies (nAbs) using the sVNT. Positive samples were tested on three automated
immunoassays targeting different viral antigens: Mindray
CL-900i®, Abbott Architect, and Ortho VITROS®.
The diagnostic sensitivity, specificity, agreement, and correlation with the sVNT
were assessed. Receiver operating characteristic (ROC) curve analysis was
performed to determine optimal thresholds for predicting the presence of
neutralizing activity by each assay. Results: All three assays
showed 100% specificities. The highest sensitivity was 99.0%, demonstrated by
VITROS®, followed by 94.3%, for CL-900i®, and
81.0%, for Architect. Both VITROS® and CL-900i®
had the strongest correlation with the sVNT (
Cite this article
41
Downloads
9
Citations
181
Views
Announcements
Open Access
Original Research
Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays
Ahmed Ismail1, Farah M. Shurrab2, Hadeel T. Al-Jighefee2,3, Duaa W. Al-Sadeq2,4, Hamda Qotba5,6, Ibrahim Abdu Al-Shaar1, Hadi. M. Yassine2,3, Laith J. Abu-Raddad7,8,9, Gheyath K. Nasrallah2,3,*
Show Less
1
Laboratory Section, Medical Commission Department, Ministry of Public Health, 42 Doha, Qatar
2
Biomedical Research Center, Qatar University, 2713 Doha, Qatar
3
Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, 2713 Doha, Qatar
4
College of Medicine, Member of QU Health, Qatar University, 2713 Doha, Qatar
5
Department of Clinical Research, Primary Health Care Centers, 26555 Doha, Qatar
6
Department of Pathology, Sidra Medicine, 26999 Doha, Qatar
7
Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation—Education City, 24144 Doha, Qatar
8
World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine—Qatar, Cornell University, Qatar Foundation—Education City, 24144 Doha, Qatar
9
Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA
*Correspondence: gheyath.nasrallah@qu.edu.qa (Gheyath K. Nasrallah)
Front. Biosci. (Landmark Ed) 2021, 26(7), 198–206;
https://doi.org/10.52586/4934
Submitted: 19 April 2021 | Revised: 22 May 2021 | Accepted: 4 June 2021 | Published: 30 July 2021
Copyright: © 2021 The Author(s). Published by BRI.
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract
Keywords
SARS-CoV-2
COVID-19
Serology
Automated immunoassay
CLIA
Neutralizing antibodies
Surrogate virus neutralization test (sVNT)
Figures
Fig. 1.